Search Results - hif-2

1 Results

Sort By:

Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic

Abstract: The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of Tempol to target HIF-2a in cancer. Elevated HIF-2a is associated with clear cell kidney cancer characterized by mutation of the...

Published: 4/8/2024 | Inventor(s): William Linehan, Tracey Rouault, James Mitchell, Murali Cherukuri

Keywords(s): clear cell, HIF-2, kidney cancer, NITROXIDE, Tempol

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics